More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS disorders

The concept of BBB penetration is anticipated to bring about a paradigm shift in modern healthcare. In fact, experts believe that there is an important relationship between the recent pandemic of Coronavirus disease (COVID-19) and cerebrovascular system, presenting commercial opportunities for players engaged in the development of BBB penetrating drugs.

 

Key Inclusions

• An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters, such as status of development (developed and under development), affiliated approach, type of compatible pharmacological molecule(s) crossing the BBB (small molecule and biologic), target receptor(s), target disease indication(s), patent availability, and licensing activity. In addition, it presents a detailed assessment of BBB technology developers and analyses based on parameters, such as year of establishment, company size, and location of headquarters.
• A detailed assessment of the current market landscape of BBB penetrant drugs (based on the abovementioned technologies), providing information on drug developer(s) (such as year of establishment, company size, and location of headquarters), phase of development (clinical, preclinical, and discovery stage), type of molecule (small molecule and biologic), affiliated BBB penetration technology, route of administration (oral, intravenous, transmucosal and others), target disease indication(s), key therapeutic area(s), and information on special drug designation (if any).
• Identification of contemporary market trends, depicted using three schematic representations, which include [A] a tree map representation of the various industry players involved in the development of BBB penetrant drugs, distributed on the basis of the target disease indication(s) of pipeline candidates and size of the companies (small, mid-sized and large companies), [B] a bubble analysis comparing the leading players engaged in the development of BBB penetrant drugs, on the basis of parameters such as pipeline strength (based on the number of drug candidates developed by a particular company, across different phases of development), number of target disease indication(s) and the size of the developer company, and [C] an informative heptagon representation, highlighting the distribution of BBB penetrant drugs across popular target disease indication(s) (based on the number of drug candidates across each target disease indication).
• An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power (based on company size and years of experience in this field) and key technology specific information, such as type of compatible pharmacological molecule(s) crossing the BBB, availability of patent protection, number of deals signed for a particular technology (2014-2020 (till March)), and popularity of the technology (in terms of the number of drugs developed using the technology).
• Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs (which are presently in both preclinical and clinical stages of development), featuring a brief overview of the company, its financial information (if available), BBB penetration technology overview, BBB penetrant product portfolio and an informed future outlook.
• An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020 (till March), covering product licensing agreements, technology licensing agreements, acquisitions and mergers, product development and commercialization agreements, research and development agreements, manufacturing agreements, service agreements and other agreements.
• An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain, including details of the rights associated with product ownership, associated royalties and upfront payments, and other contractual terms / conditions involved as a part of the agreement between various industry stakeholders.
• An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field.
• An in-depth analysis of the various patents that have been filed / granted related to BBB penetration technologies, till November 2019, taking into consideration various parameters, such as patent type, application year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, type of organization and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
• An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.
• An assessment of the most commonly targeted disorders affecting the CNS (shortlisted on the basis of number of BBB penetrant drugs in development), along with [A] an insightful 3D bubble chart highlighting the market potential of these disorders, based on the number of already approved drugs, number of pipeline drugs and the target patient population, and [B] an elaborate discussion on key epidemiological facts about specific diseases, causes, symptoms, details of BBB penetrant drugs that are being developed against them, currently available treatment options and details of already marketed drugs for each indication.

A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers, and have been shortlisted on the basis of parameters, such as developer strength (based on company size and years of experience in this field), company’s pipeline strength and maturity (based on the number of drugs and affiliated stage of development), indication overlap, molecule type overlap, route of administration, mechanism of action, and the availability of in-house delivery technology.

 

To order this 400+ page report, which features 145+ figures and 205+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html

 

The USD 940 million (by 2030) financial opportunity within the BBB market has been analyzed across the following segments:

• Type of Payment Model Adopted

• Upfront payments
• Milestone payments

 

• Type of Molecule
• Small Molecules
• Biologics

 

• Target Disease Indication

• Brain Metastases in Breast Cancer
• Glioblastoma Multiforme
• Hunter Syndrome
• Hurler Syndrome

 

• Leading Technology Platforms

• G®-Technology
• J-Brain Cargo® Technology
• LRP-1 Technology
• Trojan Horse Technology

 

• Leading Drug Developers

• 2-BBB
• Angiochem
• ArmaGen
• JCR Pharmaceuticals

 

• Key Geographical Regions
• North America
• Europe
• Asia-Pacific

 

 

The Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.”

 report features the following companies, which we identified to be key players in this domain:

• Angiochem
• ArmaGen
• BioArctic
• Cyclenium Pharma
• Denali Therapeutics
• ICB International
• Iproteos
• JCR Pharmaceuticals
• Lauren Sciences
• Medesis Pharma
• Ossianix
• Vect-Horus

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Market Landscape: Non-Invasive BBB Penetration
 

5. Market Landscape: BBB Penetrating Drugs
 

6. Company Profiles
 

7. Technology Competitiveness Analysis
 

8. Non-Invasive BBB Penetration Technologies: Popular Approaches

9. Partnerships and Collaborations
 

10. Analysis of Recent Licensing Agreements
 

11. Funding and Investment Analysis
 

12. Patent Analysis
 

13. Drug Development Strategy Analysis
 

14. Market Potential of Key Neurological Disorders

 

15. Likely Partner Analysis

 

16. Market Forecast

 

17. Conclusion

 

18. Executive Insights

 

19. Appendix 1: Tabulated Data

 

20. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]